Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Full Extent Of Clinical Trial Damage May Be Unknown Until Pandemic Ends, CBER’s Peter Marks Says

Executive Summary

More patient-centric trial designs also may be coming due to pandemic-related advances, Marks says.

You may also be interested in...



Pandemic Perspectives: US FDA, NIH Tried To Be Flexible To Keep Rare Disease Trials Going

Both federal agencies extended grants to help investigators adapt to the changes mandated by the COVID-19 pandemic.

As Pandemic Delays Reduce PDUFA Revenues, US FDA Slows Fee-Related Spending

Agency cites “unexpected and large drop in collections” in slashing user-fee-setting contract.

FDA’s COVID-19 Pandemic Plan Calls For Ongoing Clinical Trial Innovation

Broader use of adaptive trial designs and master protocols, checklist-based application review, and enhancement of real-world monitoring of products are among the recommendations of US FDA's COVID-19 Pandemic Recovery and Preparedness Plan (PREPP) report, an effort months in making based on interviews with agency management, staff, and outside stakeholders.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS143089

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel